Q1 2026 Aarti Drugs Ltd Earnings Call Transcript
Key Points
- Aarti Drugs Ltd (BOM:524348) reported a 6% year-on-year increase in total revenues for Q1 FY26, reaching INR591 crores.
- The company's gross profit margins improved by 130 basis points year-on-year to 36.8%, attributed to the normalization of input costs.
- EBITDA increased by 12% year-on-year to INR74 crores, with EBITDA margins improving to 12.6%.
- The company has commenced trial production at its greenfield project in Saykha, Gujarat, aimed at backward integration for antidiabetic products, which is expected to improve profit margins and reduce input cost volatility.
- Aarti Drugs Ltd (BOM:524348) received US FDA approval for its oncology facility and U.K. MHRA approval for its oral solid facility, enhancing its presence in regulated markets.
- Despite improved gross margins, the EBITDA margin improvement was limited due to lower capacity utilization and other expenses.
- The salicylic acid plant faced initial startup issues and is currently operating below optimal capacity, impacting financial performance.
- The company is experiencing a negative price variation of around 4.5% in the first half of FY26, affecting revenue growth.
- The US market entry is expected to take 9 to 12 months for commercial supplies, indicating a delay in capturing potential growth opportunities.
- Aarti Drugs Ltd (BOM:524348) faces competition from Chinese manufacturers, particularly in the salicylic acid market, which has led to price reductions and challenges in achieving desired margins.
Ladies and gentlemen, thank you for patiently holding. The conference will begin shortly.
Please stay connected. Please do not disconnect. Thank you.
Ladies and gentlemen, good day, and welcome to the Aarti Drugs Limited Q1 FY26 Earnings Conference Call. (Operator Instructions) Please note that this call is being recorded. With this, I now hand the conference over to Mr. Adhish Patil, COO and CFO from Aarti Drugs Limited. Thank you, and over to you, sir.
Thank you. Good morning, everyone, and thank you for joining us today for Aarti Drugs Q1 FY26 Earnings Conference Call. Joining me on the call today are Mr. Harshit Savla, our Joint Managing Director; Mr. Harit Shah, Whole-Time Director; and AJ, our Investor Relations (inaudible).
I trust you have had the chance to go through our financial results and investor presentation for the quarter, which are available on the stock exchanges and our website. Let me begin with some of the key business updates on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
